Weight loss

Weight loss is a physiological process characterized by a reduction in total body mass, typically resulting from the loss of adipose tissue, muscle mass, or fluid. In a pharmacological and clinical context, weight loss is categorized as a therapeutic outcome or medical indication rather than a specific molecular target such as a protein or receptor (NIH). It is the primary clinical endpoint for anti-obesity medications, which aim to reduce the systemic risks associated with excessive adiposity, including Type 2 diabetes, hypertension, and cardiovascular disease (CDC, StatPearls). Drugs intended to achieve weight loss interact with various distinct biological targets, most notably the Glucagon-like peptide-1 receptor (GLP-1R) and the Glucose-dependent insulinotropic polypeptide receptor (GIPR), which modulate energy balance and satiety (PubMed). Other therapeutic strategies involve the inhibition of nutrient absorption or the alteration of neurotransmitter levels to suppress appetite. Monitoring the efficacy of weight loss interventions relies on clinical metrics such as Body Mass Index (BMI) and metabolic biomarkers, while safety monitoring focuses on gastrointestinal health and the preservation of lean body mass (FDA).

Other names

Weight reductionBody mass reductionAdipose tissue lossBody weight decrease

Weight loss is a physiological outcome rather than a molecular mechanism. Pharmacological agents induce weight loss through several pathways: GLP-1 and GIP receptor agonism (promoting satiety and slowing gastric emptying), inhibition of gastric and pancreatic lipases (preventing fat absorption), or sympathomimetic activation of the central nervous system (suppressing appetite and increasing metabolic rate) (StatPearls, NIH).